Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation.

We studied leukemic stem cells (LSCs) in a Smad4(-/-) mouse model of acute myelogenous leukemia (AML) induced either by the HOXA9 gene or by the fusion oncogene NUP98-HOXA9. Although Hoxa9-Smad4 complexes accumulate in the cytoplasm of normal hematopoietic stem cells and progenitor cells (HSPCs) transduced with these oncogenes, there is no cytoplasmic stabilization of HOXA9 in Smad4(-/-) HSPCs, and as a consequence increased levels of Hoxa9 is observed in the nucleus leading to increased immortalization in vitro. Loss of Smad4 accelerates the development of leukemia in vivo because of an increase in transformation of HSPCs. Therefore, the cytoplasmic binding of Hoxa9 by Smad4 is a mechanism to protect Hoxa9-induced transformation of normal HSPCs. Because Smad4 is a potent tumor suppressor involved in growth control, we developed a strategy to modify the subcellular distribution of Smad4. We successfully disrupted the interaction between Hoxa9 and Smad4 to activate the TGF-β pathway and apoptosis, leading to a loss of LSCs. Together, these findings reveal a major role for Smad4 in the negative regulation of leukemia initiation and maintenance induced by HOXA9/NUP98-HOXA9 and provide strong evidence that antagonizing Smad4 stabilization by these oncoproteins might be a promising novel therapeutic approach in leukemia.

[1]  S. Karlsson,et al.  Canonical BMP signaling is dispensable for hematopoietic stem cell function in both adult and fetal liver hematopoiesis, but essential to preserve colon architecture. , 2010, Blood.

[2]  Wolfram Goessling,et al.  The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML , 2010, Science.

[3]  Nathan C Boles,et al.  Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. , 2010, Cell stem cell.

[4]  J. Kitzman,et al.  Acquired copy number alterations in adult acute myeloid leukemia genomes , 2009, Proceedings of the National Academy of Sciences.

[5]  M. Greaves,et al.  The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. , 2009, The Journal of clinical investigation.

[6]  G. Zhu,et al.  MH1 domain of SMAD4 binds N-terminal residues of the homeodomain of Hoxc9. , 2008, Biochimica et biophysica acta.

[7]  Göran Karlsson,et al.  Signaling pathways governing stem-cell fate. , 2008, Blood.

[8]  L. Manchon,et al.  Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. , 2007, Blood.

[9]  C. Deng,et al.  Smad4 is critical for self-renewal of hematopoietic stem cells , 2007, The Journal of experimental medicine.

[10]  S. Karlsson,et al.  Smad7 promotes self-renewal of hematopoietic stem cells. , 2006, Blood.

[11]  Yi Tang,et al.  Acute myelogenous leukemia–derived SMAD4 mutations target the protein to ubiquitin‐proteasome degradation , 2006, Human mutation.

[12]  Yi Tang,et al.  TGFbeta/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability. , 2006, The EMBO journal.

[13]  F. Ruscetti,et al.  Autocrine transforming growth factor-β regulation of hematopoiesis: many outcomes that depend on the context , 2005, Oncogene.

[14]  T. Gelehrter,et al.  Group 13 HOX proteins interact with the MH2 domain of R-Smads and modulate Smad transcriptional activation functions independent of HOX DNA-binding capability , 2005, Nucleic acids research.

[15]  D. Gilliland,et al.  Leukaemia stem cells and the evolution of cancer-stem-cell research , 2005, Nature Reviews Cancer.

[16]  Tannishtha Reya,et al.  Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance , 2005, Nature Immunology.

[17]  P. Pandolfi,et al.  Deregulated TGF-beta signaling in leukemogenesis. , 2005, Oncogene.

[18]  J. Massagué,et al.  Erratum: Transforming growth factor β-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation (Proceedings of the National Academy of Sciences of the United States of America (October 19, 2004) 101, 42 (15231-15236)) , 2004 .

[19]  J. Massagué,et al.  Transforming growth factor (cid:1) -induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation , 2022 .

[20]  N. Fox,et al.  Thrombopoietin Induces HOXA9 Nuclear Transport in Immature Hematopoietic Cells: Potential Mechanism by Which the Hormone Favorably Affects Hematopoietic Stem Cells , 2004, Molecular and Cellular Biology.

[21]  K. Mitani,et al.  Molecular mechanisms of leukemogenesis by AML1/EVI-1 , 2004, Oncogene.

[22]  M. Goumans,et al.  TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. , 2003, Blood.

[23]  I. Weissman,et al.  A role for Wnt signalling in self-renewal of haematopoietic stem cells , 2003, Nature.

[24]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. , 2003, Nature reviews. Cancer.

[25]  A. Magliocco,et al.  Microsatellite mutations of transforming growth factor-beta receptor type II and caspase-5 occur in human precursor T-cell lymphoblastic lymphomas/leukemias in vivo but are not associated with hMSH2 or hMLH1 promoter methylation. , 2003, Leukemia research.

[26]  K. Calvo,et al.  Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1 , 2002, Oncogene.

[27]  R. Humphries,et al.  Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. , 2002, Experimental hematology.

[28]  U. Thorsteinsdóttir,et al.  marrow cells induces stem cell expansion gene in bone Hoxa 9 associated − Overexpression of the myeloid leukemia , 2001 .

[29]  K. Calvo,et al.  Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: Potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  U. Thorsteinsdóttir,et al.  NUP98–HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice , 2001, The EMBO journal.

[31]  D. Baker,et al.  Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation , 2001, Nature Immunology.

[32]  Shigeru Chiba,et al.  Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis , 2001, Oncogene.

[33]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[34]  D. Scadden,et al.  Stem cell repopulation efficiency but not pool size is governed by p27kip1 , 2000, Nature Medicine.

[35]  J. Massagué,et al.  Transcriptional control by the TGF‐β/Smad signaling system , 2000 .

[36]  Xu Cao,et al.  Smad6 as a Transcriptional Corepressor* , 2000, The Journal of Biological Chemistry.

[37]  D. Scadden,et al.  Hematopoietic stem cell quiescence maintained by p21cip1/waf1. , 2000, Science.

[38]  N. Fortunel,et al.  TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. , 2000, Journal of cell science.

[39]  J. Massagué,et al.  TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.

[40]  L. Kömüves,et al.  Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias , 1999, Leukemia.

[41]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[42]  U. Thorsteinsdóttir,et al.  The Oncoprotein E2A-Pbx1a Collaborates with Hoxa9 To Acutely Transform Primary Bone Marrow Cells , 1999, Molecular and Cellular Biology.

[43]  R. Sood,et al.  MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1 , 1999, Leukemia.

[44]  M. Cleary,et al.  CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 Oncogenicity , 1999, Molecular and Cellular Biology.

[45]  Y. Yazaki,et al.  The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor-β–Mediated Growth Inhibition of Myeloid Cells , 1998 .

[46]  H. Cavé,et al.  Microsatellite instability and frameshift mutations in BAX and transforming growth factor-beta RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. , 1998, Blood.

[47]  Y. Yazaki,et al.  The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. , 1998, Blood.

[48]  F. Ruscetti,et al.  Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. , 1996, Blood.

[49]  Keisuke Toyama,et al.  The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP96 and class I homeoprotein HOXA9 , 1996, Nature Genetics.

[50]  A. Feinberg,et al.  Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia , 1996, Nature Genetics.

[51]  T. Stokke,et al.  Transforming growth factor-beta potently inhibits the viability- promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells , 1995 .

[52]  T. Stokke,et al.  Transforming growth factor-beta potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. , 1995, Blood.

[53]  G. Sauvageau,et al.  Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.